BOPSS TED Trials Webinar

7 pm Monday 12 June on Zoom

It has been a new dawn in bespoke medical therapies for thyroid eye disease since the FDA approval of Teprotumumab in the USA.

BOPSS have assembled a panel of TED Trial Investigators and other experts who can share their experiences and perspectives, to encourage wider UK participation and increase patient access to these exciting new therapies in the blossoming trial landscape.





All talks 10 mins each

Chairs Vickie Lee & Colin Dayan

1.5 CPD points (1.5 hours)

Trial Planning Stage

Route-map, Sponsorship, Feasibility
Vickie Lee PI Horizon & Viridian Trials Imperial College Healthcare NHS Trust

Building your team (Pharmacy, Labs, Operation Assessment)
Paul Meredith PI Horizon Trial Newcastle Hospitals NHS Foundation Trust

Permissions & Approval, Final Document management & Green Light
Rebecca Ford PI Viridian Trial Bristol Eye Hospital

UK as a global leader in delivering TED trials – how the NIHR CRN help
Christiana Dinah
Director, Research and Development London North West University Hospitals
Ophthalmology Specialty Co-Lead North West London Clinical Research Network

Trial Delivery Stage

Recruitment & Informed consent
Susie Morley PI Viridian Trial Guys & St Thomas’ Hospitals NHS Foundation Trust

GCP & Serious Breach Reporting Safety Reporting –
Dan Morris PI Horizon and Sling Trials University Hospital of Wales

Progress reporting CRA inspection, MHRA reporting, Substantial Amendments Addition of New Investigators
Jimmy Uddin PI Horizon & Sling Trials Moorfields Eye Hospital NHS Foundation Trust

Pearls and Pitfalls- how to manage/incorporate appropriate time and money for PI and team prospectively
Colin Dayan Professor of Clinical Diabetes and Metabolism Director of the Joint Research Office, Cardiff & Vale Health Board and Cardiff University

How to improve patient access to trials and linking up with your endocrinologist(s)
Professor Simon Pearce Professor of Endocrinology Translational & Clinical Research Institute Newcastle University

Panel Discussion & Audience Q & A

Registration is closed